These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8886702)

  • 1. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma.
    Higashijima T; Kataoka A; Nishida T; Yakushiji M
    Eur J Obstet Gynecol Reprod Biol; 1996 Sep; 68(1-2):169-73. PubMed ID: 8886702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma].
    Kurose T; Hando T; Shiota A
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):35-41. PubMed ID: 7844451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
    Wang Y; Matsuo H; Kurachi O; Maruo T
    Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
    Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
    Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri].
    Yoshioka N
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1255-60. PubMed ID: 8543851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
    Mizutani T; Sugihara A; Nakamuro K; Terada N
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
    Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
    Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
    Imai A; Matsunami K; Ichigo S; Takagi H
    Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis.
    Zhang Y; Sun L; Guo Y; Cheng J; Wang Y; Fan S; Duan H
    Obstet Gynecol Surv; 2014 Feb; 69(2):100-8. PubMed ID: 25112488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
    Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
    Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.
    Uemura T; Mori J; Yoshimura Y; Minaguchi H
    Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report.
    Volpe A; Adamo R; Coukos G; Silferi M; Artini PG; Genazzani AR
    Eur J Obstet Gynecol Reprod Biol; 1991 May; 39(3):223-5. PubMed ID: 1903347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological changes of uterine leiomyomas after GnRH agonist therapy.
    Grigoriadis C; Papaconstantinou E; Mellou A; Hassiakos D; Liapis A; Kondi-Pafiti A
    Clin Exp Obstet Gynecol; 2012; 39(2):191-4. PubMed ID: 22905461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
    Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
    Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRH analogue therapy: correlation between T2-weighted images and effect of GnRH analogue.
    Oguchi O; Mori A; Kobayashi Y; Horiuchi A; Nikaido T; Fujii S
    J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):107-17. PubMed ID: 8556572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function.
    Perrone AM; Pozzati F; Di Marcoberardino B; Rossi M; Procaccini M; Pellegrini A; Santini D; De Iaco P
    J Obstet Gynaecol Res; 2014 Jan; 40(1):117-24. PubMed ID: 24033631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.